erlotinib hydrochloride has been researched along with valproic acid in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (valproic acid) | Trials (valproic acid) | Recent Studies (post-2010) (valproic acid) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 14,155 | 1,256 | 5,108 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Bagde, A; Doddapaneni, R; Patel, K; Patki, M; Sekar, V; Singh, M | 1 |
1 trial(s) available for erlotinib hydrochloride and valproic acid
| Article | Year |
|---|---|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
1 other study(ies) available for erlotinib hydrochloride and valproic acid
| Article | Year |
|---|---|
Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Calcium Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Silicates; Solubility; Valproic Acid | 2019 |